Annual Report 2024

CHAIRMAN’S STATEMENT 9 The United Laboratories International Holdings Limited Annual Report 2024 The Group participated in seven international raw materials exhibitions, including API China, CPHI China, CPHI Milan and CPHI Middle East. During the year, the Group’s intermediate products and bulk medicine business achieved record high overseas revenue, breaking a number of sales records. With a strong foothold in China and a global presence, the Group will continue to enhance its global vision, increase brand awareness and expand its international business coverage. Environmental, Social and Governance Upholding the corporate mission of “Making Life More Valuable”, the Group has integrated the concept of sustainable development into its business operations and decision-making. The Group actively fulfills its social responsibilities by continuously investing in various areas such as education, disaster relief and community care to contribute to the society. In addition, in active response to the national policy of green and sustainable development, we are committed to promoting industrial upgrading, and facilitating the green and low-carbon transformation of enterprises. During the year, United Laboratories (Inner Mongolia) Limited ( “ Inner Mongolia Company” ) officially commenced the first phase of the salt and alkali conversion project and the biogas incineration residual heat recovery and utilization project, and fully upgraded the power supply system, with a 110 kilovolt substation completed and put into operations. By introducing advanced environmental technology and equipment, it reduced energy consumption and pollution emissions in the production process, while realizing the efficient use of resources and recycling. This symbolised Inner Mongolia Company’s firm commitment to green, efficient and intelligent production transformation and demonstrated the Group’s strong commitment to sustainable development. Outlook Looking ahead, the reform of China’s medical and healthcare system will continue to deepen. At the same time, due to multiple factors, such as the growth in demand brought about by an aging population, changes in the consumption structure of the population, and technological innovations, the development of China’s pharmaceutical market will be further expanded. Amidst the challenges and opportunities brought about by changes in the industry, the Group is confident that it will maintain its leading position in terms of comprehensive strength in the industry. We will adhere to the innovation-driven development strategy and actively reinforce the research and development of new products and technological innovation. We will consolidate our core industry strengths, further strengthen the vertically integrated industrial portfolio, while optimizing our diversified business deployment and resource allocation to accelerate the expansion of the international market, and enhancing fine scientific management to achieve continuous cost reduction and efficiency increase. We will actively capitalize on market and policy opportunities, promote high-quality and sustainable development of the Group through continuous enhancement of its overall competitiveness, and create more value for our shareholders and the society.